Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEPAROM Leberkomplex (brand name: HEPAROM® Leberkomplex) is a pharmacy-exclusive dietary supplement developed and marketed by Repha, a German family-owned pharmaceutical company. Launched on October 1, 2026, the formulation is designed to support liver health and fat metabolism. It combines the patented Novel Food ingredient ProAntro® (fermented mycelium of the Taiwanese fungus *Antrodia camphorata*) with milk thistle fruit extract, choline, vitamin E, and vitamin B12. Choline supports normal liver function and lipid metabolism, vitamin E provides antioxidant cell protection, and vitamin B12 supports energy metabolism. The product is primarily targeted at adults looking to supplement their diet for liver health, particularly individuals with metabolic conditions such as obesity or type 2 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HEPAROM Leberkomplex.